Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy : report of a large prospective multicenter trial
© 2014 by The American Society of Hematology..
This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited in 98 centers. Treatment consisted of 6 5-day chemotherapy cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy. Patients >55 years old received a reduced regimen. Rituximab was given before each cycle and twice as maintenance, for a total of 8 doses. The rate of complete remission was 88% (319/363); overall survival (OS) at 5 years, 80%; and progression-free survival, 71%; with significant difference between adolescents, adults, and elderly patients (OS rate of 90%, 84%, and 62%, respectively). Full treatment could be applied in 86% of the patients. The most important prognostic factors were International Prognostic Index (IPI) score (0-2 vs 3-5; P = .0005), age-adjusted IPI score (0-1 vs 2-3; P = .0001), and gender (male vs female; P = .004). The high cure rate in this prospective trial with a substantial number of participating hospitals demonstrates the efficacy and feasibility of chemoimmunotherapy, even in elderly patients. This trial was registered at www.clinicaltrials.gov as #NCT00199082.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:124 |
|---|---|
| Enthalten in: |
Blood - 124(2014), 26 vom: 18. Dez., Seite 3870-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoelzer, Dieter [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2015 Date Revised 21.10.2021 published: Print-Electronic ClinicalTrials.gov: NCT00199082 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood-2014-03-563627 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM243190948 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM243190948 | ||
| 003 | DE-627 | ||
| 005 | 20231224132013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood-2014-03-563627 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0810.xml |
| 035 | |a (DE-627)NLM243190948 | ||
| 035 | |a (NLM)25359988 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoelzer, Dieter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy |b report of a large prospective multicenter trial |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2015 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00199082 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 by The American Society of Hematology. | ||
| 520 | |a This largest prospective multicenter trial for adult patients with Burkitt lymphoma/leukemia aimed to prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antibody rituximab. From 2002 to 2011, 363 patients 16 to 85 years old were recruited in 98 centers. Treatment consisted of 6 5-day chemotherapy cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy. Patients >55 years old received a reduced regimen. Rituximab was given before each cycle and twice as maintenance, for a total of 8 doses. The rate of complete remission was 88% (319/363); overall survival (OS) at 5 years, 80%; and progression-free survival, 71%; with significant difference between adolescents, adults, and elderly patients (OS rate of 90%, 84%, and 62%, respectively). Full treatment could be applied in 86% of the patients. The most important prognostic factors were International Prognostic Index (IPI) score (0-2 vs 3-5; P = .0005), age-adjusted IPI score (0-1 vs 2-3; P = .0001), and gender (male vs female; P = .004). The high cure rate in this prospective trial with a substantial number of participating hospitals demonstrates the efficacy and feasibility of chemoimmunotherapy, even in elderly patients. This trial was registered at www.clinicaltrials.gov as #NCT00199082 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Antigens, CD20 |2 NLM | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Ifosfamide |2 NLM | |
| 650 | 7 | |a UM20QQM95Y |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Walewski, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Döhner, Hartmut |e verfasserin |4 aut | |
| 700 | 1 | |a Viardot, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Hiddemann, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Spiekermann, Karsten |e verfasserin |4 aut | |
| 700 | 1 | |a Serve, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Dührsen, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Hüttmann, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Thiel, Eckhard |e verfasserin |4 aut | |
| 700 | 1 | |a Dengler, Jolanta |e verfasserin |4 aut | |
| 700 | 1 | |a Kneba, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Schaich, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt-Wolf, Ingo G H |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Hertenstein, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Reichle, Albrecht |e verfasserin |4 aut | |
| 700 | 1 | |a Domanska-Czyz, Katarzyna |e verfasserin |4 aut | |
| 700 | 1 | |a Fietkau, Rainer |e verfasserin |4 aut | |
| 700 | 1 | |a Horst, Heinz-August |e verfasserin |4 aut | |
| 700 | 1 | |a Rieder, Harald |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Burmeister, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Gökbuget, Nicola |e verfasserin |4 aut | |
| 700 | 0 | |a German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 124(2014), 26 vom: 18. Dez., Seite 3870-9 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:124 |g year:2014 |g number:26 |g day:18 |g month:12 |g pages:3870-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood-2014-03-563627 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 124 |j 2014 |e 26 |b 18 |c 12 |h 3870-9 | ||